Merck KGaA’s $600 Million Acquisition of Mirus Bio Expands Offerings in Viral Vector-Based Cell and Gene Therapies

Mirus Bio, a Madison-based manufacturer of transfection regents used in gene therapies, has announced its acquisition by MilliporeSigma for $600 million. This acquisition will allow the company to expand its offerings in the field of cell and gene therapies.

Dale Gordon, CEO of Mirus Bio, expressed excitement about the acquisition. “MilliporeSigma’s broad portfolio, scale, and global reach will help take our business to new heights,” he said. He believes that the acquisition will allow them to serve more customers and patients worldwide.

MilliporeSigma’s Process Solutions business provides solutions for viral vector manufacturing, catering to cell and gene therapies from preclinical through commercial production. Their portfolio includes cell lines, culture media, processing chemicals, enzymes, and various systems and consumables essential for viral vector manufacturing processes. The Life Science Services business at Merck KGaA also offers contract testing and contract development and manufacturing organization services specifically for viral vector manufacturing.

The growing demand for viral vector-based therapies is reflected in the projected 30% growth until 2028 by Matthias Heinzel, CEO of the Life Science business at Merck KGaA. The acquisition is set to close in the third quarter of this year, marking an important milestone for both companies as they continue to expand their offerings in this field.